The final draft guidance recommends the treatment after NICE produced a review of available evidence and two separate stages of public consultation.
It continues to recommend Xgeva for the prevention of skeletal-related events in:
· people with bone metastases from breast cancer, and
· people with bone metastases from solid tumours who would otherwise be prescribed bisphosphonates.
The guidance also states that Xgeva must only be prescribed under the terms agreed in a Patient Access Scheme between Amgen and the DH.
Bone metastases occur when cancer spreads from its original tumour to the bone. This can lead to bones losing their strength and ultimately lead to skeletal-related events.
Professor Carole Longson, Director of the Centre for Health Technology Evaluation at NICE, said the condition “can severely affect a person’s quality of life” and stop individuals from completing everyday tasks.
NICE has now given consultees another opportunity to request a factual change to the draft guidance or lodge an appeal against its recommendation. If no appeals are received, final guidance will be issued later this year.